NCT04094506View on ClinicalTrials.gov

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies
Interventions
DRUG

ASP1948

Intravenous

Trial Locations (1)

Unknown

Site JP810001, Chuo-ku

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY